National Tariff Excluded Drugs List 2019-20

(Collaboration Commissioners' list of Indications that may be commissioned for excluded drugs 2019-20)

Version 14.10 CCG National Tariff Excluded Drugs (NTeD) List

Provisional list subject to publication of High Cost Drug exclusion list and and Indications for NHS England drugs list (Medicines not reimbursed through national prices and directly commissioned by NHS England)

High cost drugs excluded from the National Tariff are not commissioned by NCL Clinical Commissioning Groups (CCGs) unless the drugs and indications have approval through local processes.

Please note that the enclosed information reflects the current commissioning arrangements. These arrangements are subject to change in year if commissioning responsibility for particular drugs or services change between NCL CCGs and the NHSE and / or new local drug policies are introduced or new NICE guidance is

The pathways refered to in this document are avaialble on the JFC website accessible here: https://www.ncl-mon.nhs.uk/documentation/moc/prescribing-policies/

The tables in Appendix 1 summarise the policy on the commissioning of drugs. It is coded by a "traffic light" scheme as follows:

	Not commissioned by CCG. Where provider Trusts prescribe this treatment the funding responsibility lies with the provider and not the commissioner.
	IFR approval
	Approved for use in line with NICE Guidance or where NICE has been converted into a locally agreed protocol or NCL CCGs. Notification or individual or group prior approval required using proforma or electronic Blueteq® forms as per contract. Clinical evidence of outcomes may
	Approved for use in line with locally agreed guidance only. Prior approval, notification proformas or electronic Blueteq® may be a requirement. Indications with other minimum dataset information must be provided on back up data to invoices.
	NHSE commissioning responsibility. CCGs should not consider funding requests for these drugs in these indications / group of patients. For drugs or indications where NHS England is the responsible commissioner the current version of the NHS England drug list should be refered http://www.england.nhs.uk/commissioning/spec-services/key-docs/

Drug name	BNF section	Category	Licensed Indication/ Indication	NICE Guidance	Indications agreed for funding across NCL	Is this commissioned? What is required for funding approval?	Notes
Abaloparatide	6.4	Analogue of human parathyroid hormone-related protein	Osteoporosis- post-menopausal, with high risk of fracture	ID882	NOT COMMISSIONED	NOT COMMISSIONED	Not yet launched in U.K.
Abatacept	10.1	Cytokine modulators	Rheumatoid arthritis after failure of anti-TNF	NICE TA195, Aug 2010	In line with NICE TA195 criteria or NCL RA pathway.	Complete TBF/blueteq (using agreed local systems)	Adults only. GP prescribing NOT expected. NHS England is responsible commissioner for paediatric use until patients are transferred into adult services.
Abatacept	10.1	Cytokine modulators	Juvenile arthritis	NICE TA373, Dec 2015.	NHS ENGLAND CLINICAL COMMISSIONING POLICY: E03/P/d; TA 373	NOT COMMISSIONED	NHS England is responsible commissioner for paediatric use until patients are transferred into the adult service.
Abatacept	10.1	Cytokine modulators	Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed	NICE TA375, Jan 2016	In line with NICE TA375 criteria and NCL RA pathway.	Complete TBF/blueteq (using agreed local systems)	Adults only. GP prescribing NOT expected. NHS England is responsible commissioner for paediatric use.
Abatacept	10.1	Cytokine modulators	Psoriatic arthritis	No NICE guidance anticipated.	NOT COMMISSIONED	NOT COMMISSIONED	Adults only. GP prescribing NOT expected. NHS England is responsible commissioner for paediatric use.
Abatacept	10.1	Cytokine modulators	All other indications	No NICE guidance anticipated.	NOT COMMISSIONED	NOT COMMISSIONED	NHS England is responsible commissioner for paediatric use.
Adalimumab	10.1	Cytokine modulators	Rheumatoid arthritis	NICE TA375, Jan 2016 or TA195, Aug 2010.	In line with NICE TA375 or TA195 criteria or NCL RA pathway	Complete TBF/blueteq (using agreed local systems)	Adults only. GP prescribing NOT expected. NHS England is responsible commissioner for paediatric use until patients are transferred into adult services, Uveitis and Hidradenitis Suppurativa
Adalimumab	10.1	Cytokine modulators	Psoriatic Arthritis	NICE TA199, Aug 2010	In line with NICE criteria TA199 or NCL Psoriasis pathway (awaited as per JFC)	Complete TBF/blueteq (using agreed local systems)	Adults only. GP prescribing NOT expected. NHS England is responsible commissioner for paediatric use, uveitis and Hidradenitis Suppurativa
Adalimumab	10.1	Cytokine modulators	Ankylosing spondylitis	NICE TA383, Feb 2016.	In line with NICE TA383 criteria.	Complete TBF/blueteq (using agreed local systems)	Adults only. GP prescribing NOT expected. NHS England is responsible commissioner for paediatric use, uveitis and Hidradenitis Suppurativa
Adalimumab	13.3.1	Cytokine modulators	Psoriasis	NICE TA146, June 2008	In line with NICE TA146 criteria or NCL Psoriasis pathway (awaited as per JFC)	Complete TBF/blueteq (using agreed local systems)	Adults only. GP prescribing NOT expected. NHS England is responsible commissioner for paediatric use, uveitis and Hidradenitis Suppurativa
Adalimumab	1.1.3	Cytokine modulators	Crohn's Disease	NICE TA187, May 2010	In line with NICE TA187 criteria.	Complete TBF/blueteq (using agreed local systems)	Adults only. GP prescribing NOT expected. NHS England is responsible commissioner for paediatric use, uveitis and Hidradenitis Suppurativa
Adalimumab	10.1	Cytokine modulators	Axial spondylo-arthritis (non-radiographic)	NICE TA383, Feb 2016.	In line with NICE TA383 criteria.	Complete TBF/blueteq (using agreed local systems)	Adults only. GP prescribing NOT expected. NHS England is responsible commissioner for paediatric use, uveitis and Hidradenitis Suppurativa
Adalimumab	1.1.3	Cytokine modulators	Moderately to severely active ulcerative colitis after the failure of conventional therapy	NICE TA329, Feb 2015	In line with NICE TA329 criteria.	Complete TBF/blueteq (using agreed local systems)	Adults only. GP prescribing NOT expected. NHS England is responsible commissioner for paediatric use, uveitis and Hidradenitis Suppurativa
Adalimumab	1.1.3 10.1 13.3.1	Cytokine modulators	All other indications.	NICE TA460, July 2017 NICE TA392, June 2016 NICE TA455, July 2017 NICE TA 373, DEC 2015	NOT COMMISSIONED	NOT COMMISSIONED	NHS England is responsible commissioner for paediatric use where an adult TA is available and for JIA until patients are transferred to adult services. NHS England is responsible commissioner for uveitis in adults, bechet's, hidradenitis suppurativa and.

National Tariff Excluded Drugs List 2019-20

(Collaboration Commissioners' list of Indications that may be commissioned for excluded drugs 2019-20)

Drug name	BNF section	Category	Licensed Indication/ Indication	NICE Guidance	Indications agreed for funding across NCL	Is this commissioned? What is required for funding approval?	Notes
Afamelanotide	13	Skin conditions	Erythropoietic protoporphyria	Added to NICE highly specialised technology guidance development list Aug 2015. No due date.	NOT COMMISSIONED	NOT COMMISSIONED	Predicted UK launch 2018
Aflibercept	11.6.1	Subfoveal choroidal neovascularisation	Neovascular (wet) age-related macular degeneration.	NICE TA294, July 2013	In line with NICE TA294 criteria or NCL/NEL wAMD pathway.	Complete TBF/Blueteq (using agreed local systems)	
Aflibercept	11.6.1	Subfoveal choroidal neovascularisation	Macular oedema, secondary to CRVO	NICE TA305, Feb 2014	In line with NICE TA305 criteria or NCL/NEL CRVO pathway.	Complete TBF/Blueteq (using agreed local systems)	
Aflibercept	11.6.1	Subfoveal choroidal neovascularisation	Macular oedema, secondary to BRVO	NICE TA409, Sept 2016	In line with NICE TA409 criteria or NCL/NEL BRVO pathway.	Complete TBF/Blueteq (using agreed local systems)	
Aflibercept	11.6.1	Subfoveal choroidal neovascularisation	Choroidal neovascularisation	NICE TA486, Nov 2017	In line with NICE TA486 criteria	Complete TBF/Blueteq (using agreed local systems)	
Aflibercept	11.6.1	Subfoveal choroidal neovascularisation	Diabetic Macular Oedema	NICE TA346, July 2015	In line with NICE TA346 criteria or NCL/NEL DMO pathway.	Complete TBF/Blueteq (using agreed local systems)	
Aflibercept	11.6.1		All other indications	No NICE guidance anticipated.	NOT COMMISSIONED	NOT COMMISSIONED	
Alirocumab	2.6	PCSK9 Monoclonal Antibody Inhibitor	Primary hypercholesterolaemia or mixed dyslipidaemia (heterozygous familial and non-familial)	NICE TA393, June 2016	In line with NICE TA393 criteria.	Complete TBF/Blueteq (using agreed local systems)	
Alitretinoin	13.3.1	Skin conditions	Severe chronic hand eczema	NICE TA177, Aug 2009	In line with NICE TA177 crieria.	Complete TBF/Blueteq (using agreed local systems)	Adults only. GP prescribing NOT expected.
Amikacin Liposomal inhalation	5.2	Aminoglycosides	Nontuberculous mycobacterial lung infection	No NICE guidance anticipated.	NOT COMMISSIONED	NOT COMMISSIONED	NHS England responsible commissioner for use in CF through the IFR process.
Anakinra	10.1	Cytokine modulators	Rheumatoid arthritis	NICE CG100, July 2018 - not recommended	NOT COMMISSIONED	NOT COMMISSIONED	Adults only. GP prescribing NOT expected. NHS England responsible commissioner for adult specialised autoinflammatory disease, cryopyrin associated periodic syndrome and paediatric use
Anakinra	10.1	Cytokine modulators	Still's disease	None as yet. ID1463.	NOT COMMISSIONED	NOT COMMISSIONED	Adults only. GP prescribing NOT expected. NHS England responsible commissioner for adult specialised autoinflammatory disease, cryopyrin associated periodic syndrome and paediatric use
Apremilast	10.1	Cytokine modulators	Active psoriatic arthritis	NICE TA433, Feb 2017	In line with NICE TA433 criteria.	Complete TBF/Blueteq (using agreed local systems)	NHS England responsible commissioner for paediatric use through the IFR process.
Apremilast	10.1	Cytokine modulators	Moderate to severe plaque psoriasis	NICE TA419, Nov 2016	In line with NICE TA419 criteria or NCL Psoriasis pathway (awaited as per JFC)	Complete TBF/Blueteq (using agreed local systems)	NHS England responsible commissioner for paediatric use through the IFR process.
Apremilast	10.1	Cytokine modulators	Psoriatic arthritis in DMARD naive patients	No NICE guidance anticipated.	NOT COMMISSIONED	NOT COMMISSIONED	NHS England responsible commissioner for paediatric use through the IFR process.
Avatrombopag	9.4	Platelet disorder drugs	Thrombocytopenia associated with liver disease, pre-surgical procedure.	None as yet. ID1105. Under review/proposed.	NOT COMMISSIONED	NOT COMMISSIONED	Predicted UK launch 2019
Aztreonam Lysine nebuliser solution	5.2	Antibacterial drugs	Cystic Fibrosis / bronchiectasis	NHS England	In line with NHS England commissioning policy A01/P/b. Bronchiectasis only in line with Local Policies	NHS England	NHS England responsible commissioner for use in CF. For continuous treatment, not routinely commissioned and funding through NHS England IFR process.
Baricitinib	10.1	Cytokine modulators	Moderate to severe rheumatoid arthritis	NICE TA466, Aug 2017.	In line with NICE TA466 criteria.	Complete TBF/Blueteq (using agreed local systems)	Adults only. GP prescribing NOT expected. NHS England is responsible commissioner for paediatric use via the IFR proces.
Bortezomib			Cold aggultimin disease	IFR	IFR	IFR	via IFR process. NHS England is responsible commissioner for all other indications.
Botulinum Toxin A	4.6.1	Prophylaxis of migraine	Prevention of headaches in adults with chronic migraines	NICE TA260, June 2012	In line with NICE TA260 criteria.	Complete TBF/Blueteq (using agreed local systems)	GP prescribing NOT expected.

National Tariff Excluded Drugs List 2019-20

(Collaboration Commissioners' list of Indications that may be commissioned for excluded drugs 2019-20)

Drug name	BNF section	Category	Licensed Indication/ Indication	NICE Guidance	Indications agreed for funding across NCL	Is this commissioned? What is required for funding approval?	Notes
Botulinum Toxin A	4.1	Essential tremor, chorea, tics and related disorders	Laryngeal dystonia (spasmodic dystonia), hydradenitis suppurative, mechanical neck disorders, correction of strabismus (squint) in paediatrics, dysphagia (causes other than achalasia), Raynaud's Disease, Massateric Hypertrophy.	No NICE guidance anticipated	NOT COMMISSIONED	NOT COMMISSIONED.	Historical arrangement for BCF to reimburse for the following additional indication: achalasia, anal fissures, axillary hyperhidrosis, cerebral palsy, cervical dystonia, foream dystonia, hemifacial spasm, severe blepharospasm
Botulinum Toxin A	4.1	Essential tremor, chorea, tics and related disorders	All other indications	No NICE guidance anticipated	NOT COMMISSIONED	NOT COMMISSIONED	Historical arrangement for BCF to reimburse for the following additional indication: achalasia, anal fissures, axillary hyperhidrosis, cerebral palsy, cervical dystonia, foream dystonia, hemifacial spasm, severe blepharospasm
Botulinum Toxin A	4.1	Essential tremor, chorea, tics and related disorders	Chronic anal fissure, severe blepharospasm, hemifacial spasm, cervical dystonia (spasmodic torticollis), focal spasticity in upper and lower limb in adults (causes other than stroke), hyperhidrosis of the axillae, dysphagia caused by achalasia, overactive bladder, spasticity treatment in paediatric cerebral palsy, hypersalivation caused by disease and Hirschsprung's disease.	No NICE guidance anticipated.NICE TA ID768 no due date.	For RF & UCLH, indications covered under voice are Spasmodic /spatic dysphonia, tourette's disorder affecting the larynx, laryngeal granuloma refractory to surgery. Also spasticity and dystonia associated with human prion disease, stroke, trauma /spinal injury. (JFC Jan 2013)	Brand and Indication must be provided in SLAM	GP prescribing NOT expected.NHS England is responsible commissioner for focal spasticity in children. Treatment of spasticity in paediatric cerebral palsy is commissioned by NHSE at specialist centres. NHS England is responsible commissioner for intravesical use in spinal cord injury.
Botulinum Toxin B	4.1	Torsion, dystonias and other involuntary movements	Spasmodic torticollis (Cervical dystonia)				
Brodalumab	13.3.1	Drugs affecting the immune response	Moderate to severe plaque psoriasis	NICE TA511, Mar 2018	In line with NICE TA511 criteria.	Complete Blueteq form (using agreed local systems)	Adults only. GP prescribing NOT expected. NHS England is responsible commissioner for paediatric use through the IFR process.
Brodalumab	10.1	Drugs affecting the immune response	Psoriatic arthritis	No NICE guidance anticipated.	NOT COMMISSIONED	NOT COMMISSIONED	
Canakinumab	8.1	Immunomodulating Drugs	Cryopyrin Associated Periodic Syndroms	No NICE guidance anticipated.	NOT COMMISSIONED	NOT COMMISSIONED	NHS England responsible commissioner as per service specification (highly specialised criteria only).
Canakinumab	10.1	Immunomodulating Drugs	Juvenile Arthritis	No NICE guidance anticipated.	NOT ROUTINELY COMMISSIONED	NOT ROUTINELY COMMISSIONED	NHS England responsible commissioner for paediatric use through the IFR process.
Certolizumab Pegol	10.1	Cytokine modulators	Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed	NICE TA375, Jan 2016	In line with NICE TA375 criteria.	Complete TBF/Blueteq (using agreed local systems)	Adults only, GP prescribing NOT expected. NHS England responsible commissioner for paediatric use through the IFR process.
Certolizumab Pegol	10.1	Cytokine modulators	Rheumatoid arthritis after TNF-alpha inhibitor	NICE TA415, Oct 2016	in line with NICE TA415 criteria.	Complete TBF/Blueteq (using agreed local systems)	Adults only, GP prescribing NOT expected. NHS England responsible commissioner for paediatric use through the IFR process.
Certolizumab Pegol	10.1	Cytokine modulators	Active psoriatic arthritis after DMARDs	NICE TA445, May 2017	In line with NICE TA445 criteria.	Complete TBF/Blueteq (using agreed local systems)	Adults only, GP prescribing NOT expected. NHS England responsible commissioner for paediatric use through the IFR process.
Certolizumab Pegol	10.1	Cytokine modulators	Ankylosing spondylitis and non-radiographic axial spondyloarthritis	NICE TA383, Feb 2016	In line with NICE TA383 criteria.	Complete TBF/Blueteq (using agreed local systems)	Adults only, GP prescribing NOT expected. NHS England responsible commissioner for paediatric use through the IFR process.
Certolizumab Pegol	10.1	Cytokine modulators	All other indications.	No NICE guidance anticipated.	No NICE guidance anticipated.	NOT COMMISSIONED	
Certolizumab Pegol	13.3.1	Cytokine modulators	Moderate to severe plaque psoriasis	NICE ID1232, expected April 2019	NOT COMMISSIONED	NOT COMMISSIONED	
Co- careldopa intestinal gel (Duodopa®)	4.4.2	Parkinson's disease	Management of advanced Parkinson's disease	NHS England	NHS ENGLAND CLINICAL COMMISSIONING POLICY: D04/P/e	NHS England	NHS England is the responsible commissioner.
Colistimethate sodium dry powder for inhalation (Colobreathe®)	5.2	Antibacterial drugs	Cystic Fibrosis	NICE TA276, March 2013.	NHSE Policy -Inhaled Therapy For Adults And Children With Cystic Fibrosis Policy Ref: A01/P/b	NHS England	Only excluded when given by nebulisation/inhalation. No GP prescribing of Colobreathe® as Patient Access Scheme not available in primary care.
Colistimethate sodium powder (Promixin®) /injection for nebulisation	5.1.7	Antibacterial drugs	Cystic Fibrosis	NICE TA276, March 2013.	NHSE Policy -Inhaled Therapy For Adults And Children With Cystic Fibrosis Policy Ref: A01/P/b	NHS England	Only excluded when given by nebulisation/inhalation.

National Tariff Excluded Drugs List 2019-20

(Collaboration Commissioners' list of Indications that may be commissioned for excluded drugs 2019-20)

Drug name	BNF section	Category	Licensed Indication/ Indication	NICE Guidance	Indications agreed for funding across NCL	Is this commissioned? What is required for funding approval?	Notes
Collagenase	10.5.2	Enzymes	Dupuytren's Contracture	NICE TA459, July 2017	In line with NICE TA459 criteria.	(using agreed local systems)	Only excluded from tariff when used in outpatient
Collagenase	10.5.2	Enzymes	Peyronie's disease (PsD)	N/A	NOT COMMISSIONED	NOT COMMISSIONED	
Deferasirox	9.2	Iron overload	Anaemia related to chronic iron overload for myelodysplastic syndrome only	No NICE guidance anticipated.	Local policy being updated for MDS only	Complete proforma (using agreed local systems)	NHS England responsible commissioner for thalassemia and sickle cell disease
Deferiprone	9.2	Iron overload	Anaemia related to chronic iron overload for myelodysplastic syndrome only	No NICE guidance anticipated.	Local policy being updated for MDS only	Complete proforma (using agreed local systems)	NHS England responsible commissioner for thalassemia and sickle cell disease
Desferrioxamine	9.2	Iron overload	Anaemia related to chronic iron overload for myelodysplastic syndrome only	NICE TA suspended	Local policy being updated for MDS only	Complete proforma (using agreed local systems)	NHS England responsible commissioner for thalassemia and sickle cell disease.
Dexamethasone intravitreal implant	11.6.2	Macular oedema	Macular oedema secondary to retinal vein occlusion.	NICE TA229, July 2011.	In line with NICE TA229 criteria.	Complete TBF/Blueteq (using agreed local systems)	
Dexamethasone intravitreal implant	11.6.2	Macular oedema	Diabetic Macular Oedema	NICE TA349, July 2015	In line with NICE TA349 criteria or DMO pathway.	Complete TBF/Blueteq (using agreed local systems)	
Dexamethasone intravitreal implant	11.6.2	Macular oedema	Inflammation of the posterior segment of the eye presenting as non-infectious uveitis	NICE TA460, July 2017	In line with NICE TA460 criteria.	Complete TBF/Blueteq (using agreed local systems)	
Dibotermin alfa	N/A	Bone Morphogenetic Protein(BMP)	Acute tibia fractures	No NICE guidance anticipated.	BMP for secondary revision of spinal fusion surgery as per local commissioning policy letter dated Dec 2013	Complete proforma (using agreed local systems)	NHS England responsible commissioner for complex spinal surgery.
Digoxin immune fab	16.3.2	Poisoning	Life - threatening digoxin toxicity	National Poisons Centre Guidelines	Only commissioned in line with National Poison Centres guidelines.	Notification on SLAM.	Available on named patient basis only in the hospital.
Dimethyl fumarate	13.3.1	Preparations for psoriasis	Chronic plaque psoriasis, moderate-to-severe, **modified-release prep**	NICE TA475, Sept 2017	In line with NICE TA475 criteria.	Complete Blueteq form (using agreed local systems)	
Dimethyl fumarate	13.3.1	Preparations for psoriasis	Plaque psoriasis, moderate to severe	NICE TA475, Sept 2017	In line with NICE TA475 criteria.	Complete TBF/Blueteq (using agreed local systems)	
Dimethyl fumarate	8.1.1	Immunomodulating Drugs	relapsing-remitting multiple sclerosis	NICE TA320, Aug 2014	In line with NICE TA320 criteria.	NHS England	NHS England is responsible for commissioning for MS.
Dornase alpha	3.3.1	Mucolytics	Cystic fibrosis	NHS England	In line with NHS England Policy: A01/P/b.	NHS England	NHS England is the responsible commissioner for cystic fibrosis. NHS England is also responsible for primary ciliary dyskinesia through IFR process.
Dupilumab	13.3.1	Cytokine modulators	Moderate to severe atopic dermatitis in adults	NICE TA534, Aug 2018	In line with NICE TA534 criteria.	Complete TBF/blueteq (using agreed local systems)	NHS England is the responsible commissioner for use in astham through the IFR process.
Eculizumab	9.1.1a	Immunosuppressants	Paroxysmal nocturnal Haemoglobinuria	NHS England	In line with NHS England specialised commissioning team service specification	NHS England	NHS England is the commissioner for indications included within this category. The indications also include: - Organ rejection post kidney transplant (policy A07/P/b): Not routinely commissioned, through NHSE IFR process. - C3 Glomerulopathy (post transplant) (clinical commissioning policy16054/P) - AHUS (clinical commissioning policy E03/PS(HSS)/A NICE HST1)
Eltrombopag	9.4.2	Platelet disorder drugs	Chronic idiopathic thrombocytopenic purpura (ITP)	NICE TA293, July 2013	In line with NICE TA293 criteria.	Complete TBF/blueteq (using agreed local systems)	GP prescribing NOT expected. NHS England is the responsible commissioner for paediatric
Eltrombopag	9.4.2	Platelet disorder drugs	Thrombocytopenia in adult patients with chronic hepatitis C virus infection	No NICE guidance anticipated.	NOT COMMISSIONED	NOT COMMISSIONED	NHS England is responsible commissioner for paediatric use
Eltrombopag	9.4.2	Platelet disorder drugs	Acquired severe aplastic anaemia (SAA) refractory to prior immunosuppressive therapy	NICE TA terminated	NOT COMMISSIONED.	NOT COMMISSIONED.	NICE was unable to make recommendations on eltrombopag for severe aplastic anaemia refractory to immunosuppressive therapy because no evidence submission was received.
Eptotermin alfa	N/A	Bone morphogenic protein	Complex spinal surgery	N/A	NOT ROUTINELY COMMISSIONED	NOT ROUTINELY COMMISSIONED	NHS England is the responsible commissioner through the IFR process.
Eptotermin alfa	N/A	Bone morphogenic protein	Acute tibia fracture (adults)	NOT COMMISSIONED	NOT COMMISSIONED	NOT COMMISSIONED	
Erythropoeitin for non-dialysis renal patients	9.1.1	Drugs used in renal anaemias	Pre-dialysis	No NICE guidance anticipated.	NOT COMMISSIONED	NOT COMMISSIONED	
Epoetin (all variants)	9.1.1	Drugs used in renal anaemias	Dialysis-induced anaemia	NICE CG114	Renal Dialysis Only as per NICE CG114.	NHS England	NHS England is the responsible commissioner for dialysis-induced anaemia.
Etanercept or licensed biosimilar	10.1	Cytokine modulators	Rheumatoid arthritis	NICE TA375, Jan 2016 or TA195 Aug 2010.	In line with NICE TA373 or TA195 criteria or NCL RA pathway.	Complete TBF/Blueteq (using agreed local systems)	NHS England is responsible commissioner for paediatric use, until patients are transferred into the adult service.

National Tariff Excluded Drugs List 2019-20

(Collaboration Commissioners' list of Indications that may be commissioned for excluded drugs 2019-20)

Drug name	BNF section	Category	Licensed Indication/ Indication	NICE Guidance	Indications agreed for funding across NCL	Is this commissioned? What is required for funding approval?	Notes
Etanercept or licensed biosimilar	10.1	Cytokine modulators	Ankylosing spondylitis (adults)	NICE TA383, Feb 2016.	In line with NICE TA383 criteria.	Complete TBF/Blueteq (using agreed local systems)	NHS England is responsible commissioner for paediatric use.
Etanercept or licensed biosimilar	10.1	Cytokine modulators	Axial spondyloarthritis (non- radiographic)	NICE TA383, Feb 2016.	In line with NICE TA383 criteria.	Complete TBF/Blueteq (using agreed local systems)	NHS England is responsible commissioner for paediatric use.
Etanercept or licensed biosimilar	10.1	Cytokine modulators	Psoriatic Arthritis	NICE TA199, Aug 2010	In line with NICE TA199 criteria.	Complete TBF/Blueteq (using agreed local systems)	NHS England is responsible commissioner for paediatric use.
Etanercept or licensed biosimilar	13.3.1	Cytokine modulators	Psoriasis	NICE TA103, July 2006	In line with NICE TA103 criteria or NCL Psoriasis pathway (awaited as per JFC)	Complete TBF/Blueteq (using agreed local systems)	NHS England is responsible commissioner for paediatric use.
Etanercept or licensed biosimilar	10.1	Cytokine modulators	All other indications	No NICE guidance anticipated.	NOT COMMISSIONED.	NOT COMMISSIONED.	NHS England is responsible commissioner for paediatric use.
Evolocumab	2.6	PCSK9 Monoclonal Antibody Inhibitor	Primary hypercholesterolaemia or mixed dyslipidaemia (heterozygous familial and non-familial)	NICE TA394, Jun 2016	In line with NICE TA394 criteria.	Complete TBF/Blueteq (using agreed local systems)	
Evolocumab	2.6	PCSK9 Monoclonal Antibody Inhibitor	Homozygous familial hypercholesterolemia	NICE TA394, Jun 2016	NHS England	NHS England	NHS England is the responsible commissioner.
Fluocinolone acetonide	11.6.2	Macular oedema	Chronic diabetic macular oedema	NICE TA301, Nov 2013	in line with NICE TA301 criteria.	Complete TBF/Blueteq (using agreed local systems)	
Fomepizole	N/A	Poisoning	Poisoning	National Poisons Centre Guidelines	Only commissioned in line with National Poison Centres guidelines.	Notification on SLAM. Check with CCGs	Available on named patient basis only in the hospital.
Golimumab	10.1	Cytokine modulators	Psoriatic Arthritis	NICE TA220, April 2011	In line with NICE TA220 criteria.	Complete TBF/Blueteq (using agreed local systems)	NHS England is responsible commissioner for paediatric use.
Golimumab	10.1	Cytokine modulators	Rheumatoid arthritis	NICE TA375, Jan 2016 and TA225, June 2011	In line with NICE TA375 or TA225 criteria or NCL RA pathway	Complete TBF/Blueteq (using agreed local systems)	NHS England is responsible commissioner for paediatric use.
Golimumab	10.1	Cytokine modulators	Ankylosing spondylitis	NICE TA383, Feb 2016	In line NICE TA383 criteria.	Complete TBF/Blueteq (using agreed local systems)	NHS England is responsible commissioner for paediatric use.
Golimumab	1.1.3	Cytokine modulators	Moderately to severely active ulcerative colitis after the failure of conventional therapy	NICE TA329, Feb 2015	In line with NICE TA329 criteria.	Complete TBF/Blueteq (using agreed local systems)	NHS England is responsible commissioner for paediatric use.
Golimumab	10.1	Cytokine modulators	Axial spondyloarthritis (non- radiographic)	NICE TA383, Feb 2016 and NICE TA497, Jan 2018	In line with NICE TA383 and TA497 criteria.	Complete TBF/Blueteq (using agreed local systems)	NHS England is responsible commissioner for paediatric use.
Golimumab	10.1	Cytokine modulators	All other indications	No NICE guidance anticipated.	NOT COMMISSIONED.	NOT COMMISSIONED.	NHS England is responsible commissioner for paediatric use.
Guselkumab	13.3.1	Cytokine modulators	Moderate to severe plaque psoriasis (adults)	NICE TA521, Jun 2018	In line with NICE TA521 criteria.	Complete TBF/Blueteq (using agreed local systems)	
Iloprost	2.4.1c	Vasodilator antihypertensive drugs/Pulmanory Arterial Hypertension	Critical limb ischaemia	No NICE guidance anticipated.	NOT COMMISSIONED.	NOT COMMISSIONED	NHS England is the responsible commissioner for PAH.
Iloprost	2.4.1c	Vasodilator antihypertensive drugs/Pulmanory Arterial Hypertension	Pulmonary Arterial Hypertension	NHS England Policy	In line with NHS England clinical commissioning policy: A11/P/c	NHS England	NHS England is the responsible commissioner.
Infliximab or licensed biosimilar	1.1.3	Cytokine modulators	Crohn's disease	NICE TA187, May 2010	In line with NICE TA187 criteria.	Complete TBF/Blueteq (using agreed local systems)	NHS England is responsible commissioner for paediatric use.
Infliximab or licensed biosimilar	10.1	Cytokine modulators	Rheumatoid arthritis	NICE TA375, Jan 2016 or TA195, Aug 2010.	In line with NICE TA375 or TA195 criteria or NCL RA pathway	Complete TBF/Blueteq (using agreed local systems)	NHS England is responsible commissioner for paediatric use until transferred to adult services.
Infliximab or licensed biosimilar	10.1	Cytokine modulators	Psoriatic arthritis	NICE TA199, Aug 2010	In line with NICE TA199 criteria.	Complete TBF/Blueteq (using agreed local systems)	NHS England is responsible commissioner for paediatric use.
Infliximab or licensed biosimilar	13.3.1	Cytokine modulators	Psoriasis (adults)	NICE TA134, Jan 2008	In line with NICE TA134 criteria or NCL Psoriasis pathway (awaited as per JFC)	Complete TBF/Blueteq (using agreed local systems)	NHS England is responsible commissioner for paediatric use.

National Tariff Excluded Drugs List 2019-20

(Collaboration Commissioners' list of Indications that may be commissioned for excluded drugs 2019-20)

Drug name	BNF section	Category	Licensed Indication/ Indication	NICE Guidance	Indications agreed for funding across NCL	Is this commissioned? What is required for funding approval?	Notes
Infliximab or licensed biosimilar	1.1.3	Cytokine modulators	Ulcerative colitis (acute exacerbations)	NICE TA163, Dec 2008	In line with NICE TA163 criteria.	Complete TBF/Blueteq (using agreed local systems)	NHS England is responsible commissioner for paediatric use.
Infliximab or licensed biosimilar	10.1	Cytokine modulators	Ankylosing spondylitis and non-radiographic axial spondyloarthritis	NICE TA383, Feb 2016.	In line with NICE TA383 criteria.	Complete TBF/Blueteq (using agreed local systems)	NHS England is responsible commissioner for paediatric use.
Infliximab or licensed biosimilar	1.1.3	Cytokine modulators	Moderately to severely active ulcerative colitis after the failure of conventional therapy	NICE TA329, Feb 2015	In line with NICE TA329 criteria.	Complete TBF/Blueteq (using agreed local systems)	NHS England is responsible commissioner for paediatric use.
Infliximab or licensed biosimilar	1.1.3 10.1 13.3.1	Cytokine modulators	All other indications		NOT COMMISSIONED.	NOT COMMISSIONED.	NHS England is responsible commissioner for paediatric use. NHS England is also commissioner for uveitis, connective tissue disease- interstitial lung disease, graft versus host disease, renal, sarcoidosis and hidradentis suppurativa via the IFR process. NHS England are commissioner for behcets syndrome as per highly specialised criteria only.
Ixekizumab	13.3.1	Humanized anti–interleukin-17 monoclonal antibody	Active psoriatic arthritis in adult patients who have responded inadequately to, or who are intolerant to one or more DMARD therapies	NICE TA537, Aug 2018	In line with NICE TA 537 criteria.	Complete TBF/Blueteq (using agreed local systems)	
Ixekizumab	13.3.1	Humanized anti–interleukin-17 monoclonal antibody	Moderate to severe plaque psoriasis	NICE TA442, April 2017	In line with NICE TA442 criteria.	Complete TBF/Blueteq (using agreed local systems)	
Ixekizumab	10.1	Humanized anti–interleukin-17 monoclonal antibody	Ankylosing spondylitis	No NICE guidance anticipated.	NOT COMMISSIONED	NOT COMMISSIONED	
Ixekizumab	10.1	Humanized anti–interleukin-17 monoclonal antibody	Psoriatic arthritis	No NICE guidance anticipated.	NOT COMMISSIONED	NOT COMMISSIONED	
Lanreotide	8.4	Somatostatin Analogues	All indications except acromegaly, cancer and congenital hyperinsulinism	No NICE guidance anticipated.	Only in line with Local Policies	Complete proforma (using agreed local systems)	NHS England is responsible commissioner for acromegaly, cancer and congenital hyperinsulinism funded by NHS England.
Levofloxacin Solution for Inhalation	5.2	Antibacterial drugs	Chronic pulmonary infections due to Pseudomonas aeruginosa in adults with CF	No NICE guidance anticipated.	NOT ROUTINELY COMMISSIONED	NOT ROUTINELY COMMISSIONED	NHS England fund through IFR Approval process.
Lomitapide	2.6	Lipid-regulating drugs	Hypercholesterolaemia, homozygous familial (HoFH).	No NICE guidance anticipated.	NOT ROUTINELY COMMISSIONED	NOT ROUTINELY COMMISSIONED	NHS England fund through IFR Approval process.
Mannitol	3.3.1	Mucolytics	Indications other than cystic fibrosis	No NICE guidance anticipated.	NOT COMMISSIONED	NOT COMMISSIONED	
Mannitol	3.3.1	Mucolytics	Cystic Fibrosis	NICE TA266, Nov 2012	In line with NICE TA266 criteria and NHSE A01/P/b		NHS England is responsible commissioner. No GP prescribing for paediatric use.
Ocriplasmin	11.6.4	Retinal disorders	Vitreomacular traction including those associated with macular holes.	NICE TA297, Oct 2013	In line with NICE TA297 criteria.	Complete proforma (using agreed local systems)	
Octreotide	8.4	Somatostatin Analogues	All indications except acromegaly, cancer and congenital hyperinsulinism	No NICE guidance anticipated.	Only in line with Local Policies	Complete proforma (using agreed local systems)	NHS England is commissioner for acromegaly, cancer and congenital hyperinsulinism funded by NHS England.
Odanacatib	6.4	Selective cathepsin-K inhibitor	Postmenopausal osteoporosis	No NICE guidance anticipated.	NOT COMMISSIONED	NOT COMMISSIONED	Development of this drug has been discontinued.
Odanacatib	6.4	Selective cathepsin-K inhibitor	Osteoporosis in men	No NICE guidance anticipated.	NOT COMMISSIONED	NOT COMMISSIONED	Development of this drug has been discontinued.
Omalizumab	3.1	Allergen Immunotherapy	Previously treated chronic spontaneous urticaria	NICE TA339, June 2015	In line with NICE TA339 criteria	Complete TBF/Blueteq (using agreed local systems)	NHS England is responsible commissioner for Asthma.
Parenteral Nutrition	9.4	Parenteral nutrition-adults	Intestinal failure	NICE CG32. Feb 2006	Only in line with Local Policies (using agreed systems)	Only in line with Local Policies (using agreed systems)	NHSE is responsible for: Children and Adult specialist intestinal failure services for patients with Intestinal Failure Type II and Type III (including the provision of home parenteral nutrition).
Pasireotide	8.4	Somatostatin Analogues	Acromegaly	No NICE guidance anticipated.	In line with NHS England policy 16003/P.	NHS England	NHS England is responsible commissioner through IFR approval.
Pasireotide	8.4	Somatostatin Analogues	Cushings Syndrome (3rd line adults)	No NICE guidance anticipated.	In line with NHS England:16052/P	NHS England	Adults only. GP prescribing not expected
Pegaptanib	11.6.1	Subfoveal choroidal neovascularisation	Neovascular (wet) age-related macular degeneration	NICE TA155, Aug 2008	NOT COMMISSIONED	NOT COMMISSIONED	NICE TA155 1.3 Pegaptanib is not recommended for the treatment of wet age-related macular degeneration.
Pegpleranib	11.6.1	Retinal disorders/intraocular lens replacement surgery	Wet ARMD (age-related macular degeneration)	No NICE guidance anticipated.	NOT COMMISSIONED	NOT COMMISSIONED	Not yet licensed in UK. UK development has been discontinued.

National Tariff Excluded Drugs List 2019-20

(Collaboration Commissioners' list of Indications that may be commissioned for excluded drugs 2019-20)

Drug name	BNF section	Category	Licensed Indication/ Indication	NICE Guidance	Indications agreed for funding across NCL	Is this commissioned? What is required for funding approval?	Notes
Phenylephrine with Ketorolac	11.4.1	Retinal disorders / intraocular lens replacement surgery	Intraocular lense replacement surgery	No NICE guidance anticipated.	NOT COMMISSIONED	NOT COMMISSIONED	
Ranibizumab	11.6.1	Neovascularisation	Neovascular (wet) age-related macular degeneration	NICE TA155, Aug 2008	In line with NICE crteria TA155 criteria or NCL/NEL wAMD pathway	Complete TBF/Blueteq (using agreed local systems)	
Ranibizumab	11.6.1	Neovascularisation	Diabetic macular oedema	NICE TA274, Feb 2013	In line with NICE TA274 criteria or NCL/NEL wAMD pathway	Complete TBF/Blueteq (using agreed local systems)	
Ranibizumab	11.6.1	Neovascularisation	Macular oedema (retinal vein occlusion)	NICE TA283, May 2013	In line with NICE TA283 criteria or NCL/NEL wAMD pathway	Complete TBF/Blueteq (using agreed local systems)	
Ranibizumab	11.6.1	Neovascularisation	CNV due to pathological myopia	NICE TA298, Nov 2013	In line with NICE TA298 criteria or NCL/NEL wAMD pathway	Complete TBF/Blueteq (using agreed local systems)	
Riluzole	10.3	Torsion Dystonia and other involuntary movements	ALS form of Motor Neurone Disease	NICE TA20, Jan 2001	In line with NICE TA20 criteria	Complete TBF/Blueteq (using agreed local systems)	Adults only.
Rituximab or licensed biosimilar	10.1	Cytokine modulators	Rheumatoid arthritis after failure of TNF inhibitor	NICE TA195, Aug 2010	In line with NICE TA195 criteria	Complete TBF/Blueteq (using agreed local systems)	Adults only. GP prescribing not expected. NHS England is responsible commissioner for cancerous and specialist auto-inflammatotory conditions.
Rituximab or licensed biosimilar	10.1	Cytokine modulators	Rheumatoid arthritis (first line)	No NICE guidance anticipated.	See JFC pathway	NOT COMMISSIONED	Adults only. NHS England is responsible commissioner for cancerous and specialist auto-inflammatotory conditions.
Rituximab or licensed biosimilar	N/A	Cytokine modulators	Autoimmune Haemolytic Anaemia (AIHA).	No NICE guidance anticipated.	In line with JFC: For AIHA. July 2016	Notification through SLAM (using agreed local systems)	Adults only. NHS England is responsible commissioner for cancerous and specialist auto-inflammatotory conditions.
Rituximab or licensed biosimilar	N/A	Cytokine modulators	ITP	No NICE guidance anticipated.	In line with JFC: For refractory or relapsed disease only (November 2012)	Complete TBF/Blueteq (using agreed local systems)	Adults only. NHS England is responsible commissioner for cancerous and specialist auto-inflammatotory conditions.
Rituximab or licensed biosimilar	10.1	Cytokine modulators	ANCA-positive vasculitis	NICE TA308, Mar 2014	In line with NICE TA 308 and NHS England policy A13/P/a	NHS England	Adults only.No GP prescribing. NHS England is responsible commissioner for cancerous and specialist auto-inflammatotory conditions.
Rituximab or licensed biosimilar	10.1	Cytokine modulators	Juvenile Arthritis	NHS England Policy	In line with NHS England policy: E03/P/d	NHS England	No GP prescribing. NHS England is responsible commissioner for cancerous and specialist auto-inflammatotory conditions.
Rituximab or licensed biosimilar	N/A	Cytokine modulators	Neuromyelitis optica	NHS England	In line with NHS England specification	NHS England	The first 2 courses of Rituximab, i.e. 1st month and 6th month (1 course=2 injections on day 1 and day 14) will be given and funded by NHS England commissioned centres. The central budget for Rituximab is held by The Walton Centre NHS Foundation Trust and that Oxford will cross charge Rituximab to the Walton Centre based on use. The centres will assess benefit after the second course of treatment and if ongoing care is needed Rituximab may be given locally as part of a shared care arrangement. On-going drug funding will be the responsibility of the patient's CCG.
Rituximab or licensed biosimilar	10.1	Cytokine modulators	Other indications (adults) used in CCG commissioned service			NHS England responsibility	Adults only.No GP prescribing. NHS England is responsible commissioner for cancerous and specialist auto-inflammatotory conditions.
Romiplostim	9.4.2	Platelet Disorder Drugs	Chronic immune (idiopathic) thrombocytopenic purpura	NICE TA221, April 2011	In line with NICE TA221 criteria	Complete TBF/Blueteq (using agreed local systems)	Adults only. GP prescribing NOT expected. NHS England is responsible commissioner for paediatric use.
Sarilumab	10.1	Cytokine modulators	Rheumatoid arthritis	NICE TA485, Nov 2017	In line with NICE TA485 criteria.	Complete TBF/blueteq (using agreed local systems)	Adults only. GP prescribing NOT expected. NHS England responsible commissioner for paediatric use through IFR process.
Secukinumab	10.1	Cytokine modulators	Ankylosing spondylitis after treatment with non-steroidal anti-inflammatory drugs or TNF-alpha inhibitors	NICE TA407, Sept 2016	In line with NICE TA407 criteria.	Complete TBF/Blueteq (using agreed local systems)	Adults only. GP prescribing NOT expected. NHS England responsible commissioner for paediatric use through IFR process.
Secukinumab	13.3.1	Cytokine modulators	Moderate to severe plaque psoriasis	NICE TA350, July 2015.	In line with NICE TA350 criteria.	Complete TBF/Blueteq (using agreed local systems)	Adults only. GP prescribing NOT expected. NHS England responsible commissioner for paediatric use through IFR process.
Secukinumab	10.1	Cytokine modulators	Active psoriatic arthritis after DMARDs	NICE TA445, May 2017	In line with NICE TA445 criteria.	Complete TBF/Blueteq (using agreed local systems)	Adults only. GP prescribing NOT expected. NHS England responsible commissioner for paediatric use through IFR process.
Secukinumab	10.1	Cytokine modulators	Rheumatoid arthritis	No NICE guidance anticipated.	NOT COMMISSIONED	NOT COMMISSIONED	Not yet licensed in UK. NHS England responsible for paediatric indication
Serelaxin	N/A	Hypertension and Heart failure	Heart failure	NICE Guidance ID673	NOT COMMISSIONED	NOT COMMISSIONED	Not yet licensed in UK. UK development has been discontinued. Appraisal suspended indefinitely.
Siltuximab	10.1	Cytokine modulators	Castleman's disease	No NICE guidance anticipated.	NOT COMMISSIONED	NOT COMMISSIONED	

National Tariff Excluded Drugs List 2019-20

(Collaboration Commissioners' list of Indications that may be commissioned for excluded drugs 2019-20)

Drug name	BNF section	Category	Licensed Indication/ Indication	NICE Guidance	Indications agreed for funding across NCL	Is this commissioned? What is required for funding approval?	Notes
Sirukumab	10.1	Cytokine modulators	Rheumatoid arthritis	No NICE guidance anticipated.	NOT COMMISSIONED	NOT COMMISSIONED	Company decided to withdraw its marketing authorisation application. Consequently, appraisal suspended in October 2017.
Sodium oxybate	4.7.2	Hypnotics and anxiolytics	Narcolepsy with cataplexy (adults)	No NICE guidance anticipated.	local policy being updated	Complete using agreed local systems	NHS England is responsible commissioner for paediatric services in line with clinical commissioning policy 16065/P.
Somatropin (adults)	6.7.4	Growth Hormone or Growth Hormone Receptor Antagonist	Growth hormone deficiency	NICE TA64, Aug 2003	In line with NICE TA64 criteria.	Complete TBF/Blueteq (using agreed local systems)	NHS England is responsible for indications falling outside NICE guidance treated in specialist centres
Somatropin (children)	6.7.4	Growth Hormone or Growth Hormone Receptor Antagonist	Growth failure in children	NICE TA188, May 2010	In line with NICE TA188 criteria.	Complete TBF/Blueteq (using agreed local systems)	NHS England is responsible for indications falling outside NICE guidance treated in specialist centres
Tafamidis	4.4.1	Neuroprotective agents	Treatment of transthyretin amyloidosis in adult patients with stage 1 symptomatic polyneuropathy to delay peripheral neurologic impairment	N/A	NOT COMMISSIONED	NOT COMMISSIONED	Current development status of this drug is unknown
Teriflunomide	8.1.1	Other immunomodulating drugs	Relapsing–remitting multiple sclerosis	NICE TA303, Jan 2014 and NHS England Policy	In line with NICE TA303 criteria and NHS England Policy: D04/P/b	NHS England	NHS England is responsible commissioner.
Teriparatide	6.4	Drugs affecting bone metabolism	Secondary prevention of osteoporotic fragility fractures in postmenopausal women	NICE TA161, Oct 2008	In line with NICE TA161 criteria	Complete TBF/Blueteq (using agreed local systems)	
Teriparatide	6.4	Drugs affecting bone metabolism	Treatment of osteoporosis associated with glucocorticoids	No NICE guidance anticipated.	NOT COMMISSIONED	NOT COMMISSIONED	
Teriparatide	6.4	Drugs affecting bone metabolism	Osteogenesis imperfecta	NHS England Policy	Not routinely commissioned. In line with NICE policy 16002/P	NHS England	NHS England are the responsible commissioner through the IFR process.
Teriparatide	6.4	Drugs affecting bone metabolism	Male and juvenile osteoporosis	NHS England	Not routinely commissioned. In line with IFR approval.	NHS England	NHS England are the responsible commissioner through the IFR process.
Tesamorelin	N/A	Growth Hormone & growth hormone Receptor Antagonist	HIV associated lipodystrophy	No NICE guidance anticipated.	NOT COMMISSIONED	NOT COMMISSIONED	Filing for this drug has been withdrawn
Thrombomodulin, Recombinant Human	N/A	Fibrinolytics	Septic shock (Sepsis) (adult, non-specialist services)	No NICE guidance anticipated.	NOT COMMISSIONED	NOT COMMISSIONED	Launch expected 2019
Tildrakizumab	N/A	Skin conditions	Psoriasis (adults)	No NICE guidance. ID1060	NOT COMMISSIONED	NOT COMMISSIONED	Expected launch April 2019
Tobramycin (Tobi® / Bramitob®) nebuliser solution	5.2	Antibacterial Drugs	Cystic fibrosis	NICE TA276, Mar 2013	In line with NICE TA276 criteria & NHS England Policy:A01/P/b	NHS England	NHS England is the responsible commissioner.
Tobramycin (Tobi® Podhaler) dry powder for inhalation	5.2	Antibacterial Drugs	Cystic fibrosis	NICE TA276, Mar 2013.	In line with NICE TA276 criteria & NHS England Policy:A01/P/b	NHS England	NHS England is the responsible commissioner.
Tocilizumab	10.1	Cytokine modulator	Rheumatoid arthritis	NICE TA247, Feb 2012 or TA375, Jan 2016	In line with NICE crteria TA247 or TA375 criteria.	Complete TBF/Blueteq (using agreed local systems)	Adults only. GP prescribing NOT expected. NHS England is responsible commissioner for paediatric use until transferred to adult service.
Tocilizumab	10.1	Cytokine modulator	Juvenile arthritis	NICE TA373, Dec 2015 and NHS England commissioning Policy	In line with NICE TA373 and NHS England commissioning policy E03/P/d	NHS England	NHS England is responsible commissioner for juvenile arthritis in paediatrics, until transferred into adult service.
Tocilizumab	10.1	Cytokine modulator	Other indications (adults) used in CCG commissioned service	No NICE guidance anticipated.	NOT COMMISSIONED	NOT COMMISSIONED	
Tocilizumab	10.1	Cytokine modulator	Takayasu arteritis	NHS England clinical commissioning policy	In line with NHS England commissioning policy:16056/P	NHS England	NHS England is the responsible commissioner.
Tocilizumab	10.1	Cytokine modulator	Giant Cell Arteritis	NICE TA518, Apr 2018 and NHS England Policy.	Not routinely commissioned. In line with TA518 and NHS England Policy 16019/P	Not routinely commissioned. NHS England.	NHS England is the responsible commissioner through the IFR process.
Tofacitinib	10.1	Cytokine modulator	Moderate to severe rheumatoid arthritis	NICE TA480, Oct 2017	In line with NICE TA480 criteria.	Complete TBF/Blueteq (using agreed local systems)	Adults only. GP prescribing NOT expected. NHS England is responsible commissioner for paediatric use through the IFR process.

National Tariff Excluded Drugs List 2019-20

(Collaboration Commissioners' list of Indications that may be commissioned for excluded drugs 2019-20)

Drug name	BNF section	Category	Licensed Indication/ Indication	NICE Guidance	Indications agreed for funding across NCL	Is this commissioned? What is required for funding approval?	Notes
Tofacitinib	10.1	Cytokine modulator	Treating active psoriatic arthritis after inadequate response to DMARDs	NICE TA543, Oct 2018	In line with NICE TA543 criteria.	Complete TBF/Blueteq (using agreed local systems)	Adults only. GP prescribing NOT expected. NHS England is responsible commissioner for paediatric use through the IFR process.
Tofacitinib	1.1.3	Cytokine modulator	Moderately to severely active ulcerative colitis	NICE TA547, Nov 2018	In line with NICE TA547 criteria.	Complete TBF/Blueteq (using agreed local systems)	Adults only. GP prescribing NOT expected. NHS England is responsible commissioner for paediatric use through the IFR process.
Tofacitinib	13.3.1	Cytokine modulator	Psoriasis (adults)	No NICE guidance anticipated.	NOT COMMISSIONED	NOT COMMISSIONED	UK development for this has been discontinued.
Tofacitinib	10.1	Cytokine modulator	Juvenile arthritis	No NICE guidance anticipated.	NOT COMMISSIONED	NOT COMMISSIONED	Adults only. GP prescribing NOT expected. NHS England is responsible commissioner for paediatric use through the IFR process.
Tolvaptan	6.1.2	Vasopressin V2-receptor antagonist	Autosomal dominant polycystic kidney disease, stage 2 or 3, rapidly progressing	NICE TA358, Oct 2015	In line with NICE TA358 criteria.	Complete TBF/Blueteq (using agreed local systems)	No GP prescribing. NHS England is responsible commissioner for hyponatraemia in cancer.
Tolvaptan	6.1.2	Vasopressin V2-receptor antagonist	Hyponatraemia due to syndrome of inappropriate antidiuretic hormone secretion (SIADH).	No NICE guidance anticipated.	NOT COMMISSIONED	NOT COMMISSIONED	No GP prescribing. NHS England is responsible commissioner for hyponatraemia in cancer.
Tolvaptan	6.1.2	Vasopressin V2-receptor antagonist	Hyponatraemia from other causes and other endocrine uses	No NICE guidance anticipated.	NOT COMMISSIONED	NOT COMMISSIONED	No GP prescribing. NHS England is responsible commissioner for hyponatraemia in cancer.
Ustekinumab	13.3.1	Drugs affecting the immune response	Psoriasis moderate to severe	NICE TA180, Sept 2009.	In line with NICE crteria TA180 criteria or NCL Psoriasis pathway (awaited as per JFC)	Complete TBF/Blueteq (using agreed local systems)	Adults only. GP prescribing NOT expected. NHS England is responsible commissioner for paediatric use.
Ustekinumab	1.1.3	Drugs affecting the immune response	Crohn's disease	NICE TA456, July 2017	In line with NICE TA456 criteria.	Complete TBF/Blueteq (using agreed local systems)	Adults only. GP prescribing NOT expected. NHS England is responsible commissioner for paediatric use.
Ustekinumab	10.1	Drugs affecting the immune response	Active psoriatic arthritis	NICE TA340, June 2015	In line with NICE TA340 criteria.	Complete TBF/Blueteq (using agreed local systems)	Adults only. GP prescribing NOT expected. NHS England is responsible commissioner for paediatric use.
Ustekinumab	13.3.1	Drugs affecting the immune response	Plaque psoriasis in children and young people	NICE TA455, July 2017	In line with NICE TA455 criteria.	NHS England	NHS England is responsible commissioner.
Vedolizumab	1.1.3	Drugs affecting the immune response	Crohn's disease second line after conventional therapy and TNF inhibitors	NICE TA352, Aug 2015	In line with NICE TA352 criteria.	Complete TBF/Blueteq (using agreed local systems)	Adults only. GP prescribing NOT expected. NHS England is responsible commissioner for paediatric use.
Vedolizumab	1.1.3	Drugs affecting the immune response	Moderately to severely active ulcerative colitis	NICE TA342, June 2015	In line with NICE TA342 criteria.	Complete TBF/Blueteq (using agreed local systems)	Adults only. GP prescribing NOT expected. NHS England is responsible commissioner for paediatric use.
Verteporfin	11.6.1	Subfoveal choroidal neovascularisation	Photodynamic therapy for wet age-related macular degeneration.	NICE TA68, Sept 2003	In line with local policies	Complete TBF/Blueteq (using agreed local systems)	No GP prescribing

Last reviewed: March 2019